This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Apr 6;43(14):1413-1415.

doi: 10.1093/eurheartj/ehab890.

Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?

Robert A Hegele¹

Affiliations

PMID: 35174387
DOI: 10.1093/eurheartj/ehab890

Editorial

Apolipoprotein C-III inhibition to lower triglycerides: one ring to rule them all?

Robert A Hegele. Eur Heart J. 2022.

. 2022 Apr 6;43(14):1413-1415.

doi: 10.1093/eurheartj/ehab890.

Author

Robert A Hegele¹

Affiliation

¹ Department of Medicine and Robarts Research Institute, Western University, London, Ontario, Canada N6A 5B7.

PMID: 35174387
DOI: 10.1093/eurheartj/ehab890

No abstract available

PubMed Disclaimer

Comment on

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.
Tardif JC, Karwatowska-Prokopczuk E, Amour ES, Ballantyne CM, Shapiro MD, Moriarty PM, Baum SJ, Hurh E, Bartlett VJ, Kingsbury J, Figueroa AL, Alexander VJ, Tami J, Witztum JL, Geary RS, O'Dea LSL, Tsimikas S, Gaudet D. Tardif JC, et al. Eur Heart J. 2022 Apr 6;43(14):1401-1412. doi: 10.1093/eurheartj/ehab820. Eur Heart J. 2022. PMID: 35025993 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

CIHR/Canada

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information